1.2Single extended release dose
A hydrophilic polymer matrix hydrates in gastrointestinal fluid and controls drug release through diffusion and erosion. The release profile distributes delivery over several hours after the tablet is swallowed.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A hydrophilic polymer matrix hydrates in gastrointestinal fluid and controls drug release through diffusion and erosion. The release profile distributes delivery over several hours after the tablet is swallowed.
A medium-chain triglyceride and surfactant vehicle carries dissolved allopregnanolone and disperses it into droplets when mixed with gastrointestinal fluid. A calibrated oral syringe measures the volume from the formulation concentration and the required drug mass.
One tablet supplies the full daily amount at a scheduled administration. Serial plasma samples characterize exposure, and a symptom scale tracks clinical response during the regimen.
A polymer-coated multiparticulate formulation meters release over several hours to limit the early rise in plasma concentration. Serial samples collected after a standardized meal establish the observed peak and the area under the concentration-time curve.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A veterinary pharmacokinetic study uses solid oral allopregnanolone units in a repeated-dose regimen with species-specific dose levels. Study staff record administration, feeding, and blood collection times for each animal. A laboratory measures plasma allopregnanolone by liquid chromatography coupled to tandem mass spectrometry and reports the highest observed concentration for each sampling interval.
A hard hydroxypropyl methylcellulose capsule filled with compressed allopregnanolone minitablets replaces a single compressed tablet. Each minitablet contains a fixed amount of allopregnanolone, and the capsule fill count determines the total drug content per unit. After ingestion, the capsule shell opens and the minitablets disperse in gastrointestinal fluid.
A solid oral unit contains 200 mg of allopregnanolone. A repeated twice-daily regimen assigns one unit at 08:00 and two units at 20:00, for 600 mg per day. Plasma samples collected after each administration provide separate observed morning and evening peak concentrations.
A solid oral unit contains 150 mg of allopregnanolone. A repeated regimen assigns one unit at 07:00, 12:00, 17:00, and 22:00, for 600 mg per day. The schedule creates three 5-hour daytime intervals and one 9-hour overnight interval.
A calendar blister card holds solid oral allopregnanolone units in cavities labeled by day and administration time. A barcode on each card encodes a package identifier that links to the scheduled regimen in an electronic medication administration record. At each administration, staff scan the card and record the number of units given and the actual administration time.
Software imports dose timestamps, meal timestamps, sample collection timestamps, and plasma allopregnanolone concentrations. It assigns each sample to the interval following the most recent recorded administration and classifies each interval using a configured meal-timing rule. For each interval, it reports the highest measured concentration and its elapsed time from administration, with separate summaries for fed and fasted intervals.
A tablet press compresses a blend of micronized allopregnanolone, microcrystalline cellulose, and a disintegrant into 50 mg units. Four tablets supply 200 mg at one administration.
A hard capsule contains 200 mg of micronized allopregnanolone blended with microcrystalline cellulose and a wetting agent. The shell dissolves after swallowing and releases the powder into gastrointestinal fluid.
A blister card groups each day's doses into morning and evening compartments. The subject takes the two doses approximately 12 hours apart.
A unit-dose blister holds two tablets, each containing 100 mg of allopregnanolone. The subject swallows both tablets at the same administration to receive 200 mg.
The subject takes the solid oral dose after an overnight fast, and serial plasma samples span the expected time of peak concentration. Liquid chromatography coupled with tandem mass spectrometry quantifies allopregnanolone, and the highest measured concentration is compared with 9 ng/mL.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
Generally, the total daily dosage will be at least about 10 mg and more preferably at least about 50 mg, and preferably not more than 500 mg per day, administered orally. Capsules or tablets for oral delivery can contain up to a full daily oral dose, e.g., 100 mg or more.A · US 2010/0105646 A1 · ¶ 86
The compositions can be administered in a single dose or multiple doses.A · US 2010/0105646 A1 · ¶ 12
In some embodiments, the method includes a course of treatment with multiple dosages or cycles of treatment (e.g., a first dose or cycle of treatment is a parenteral dose such as an i.v. dose, and a second dose or cycle of treatment is an oral dose).B · US 10,940,156 B2 · ¶ 23
With oral dosing, one to five and especially two to four and typically three oral doses per day are representative regimens.B · US 10,940,156 B2 · ¶ 297
Preferably, these formulations are employed in solid dosage forms suitable for simple, and preferably oral, administration of precise dosages. Solid dosage forms for oral administration include, but are not limited to, tablets, soft or hard gelatin or non-gelatin capsules, and caplets.A · US 2010/0105646 A1 · ¶ 48
The term “unit dosage forms” refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Typical unit dosage forms include prefilled, premeasured ampules or syringes of the liquid compositions or pills, tablets, capsules or the like in the case of solid compositions.B · US 10,940,156 B2 · ¶ 296
Generally, the total daily dosage will be at least about 10 mg and more preferably at least about 50 mg, and preferably not more than 500 mg per day, administered orally.A · US 2010/0105646 A1 · ¶ 86
In an aspect, provided is a method for treating or preventing a disorder described herein, comprising orally administering a total daily dose of Compound 9, or pharmaceutically acceptable salt or isotopologue thereof, or pharmaceutical composition thereof of about 10 mg to about 100 mg to a subject in need thereof.B · US 10,940,156 B2 · ¶ 94
An empty cell means only that no passage was reproduced there.
This invention is in the field of pharmaceutical compositions for enhancing neurological function and methods of use thereof, particularly compositions containing allopregnanolone or a derivative or analogue thereof.A · US 2010/0105646 A1 · ¶ 2
Accordingly, there is a need for new treatment modalities directed to improving the adverse neurological conditions associated with neuropathies, neurological injuries and age-related neurological decline or impairment.A · US 2010/0105646 A1 · ¶ 8
There is increasing evidence to support the use of neuroactive steroids, e.g., a neuroactive steroid as described herein, e.g., progesterone and its metabolites; in the treatment and prevention of tremor (e.g., essential tremor), depression (e.g., postpartum depression, major depressive disorder), and anxiety disorder.B · US 10,940,156 B2 · ¶ 5
In some embodiments, the neuroactive steroid is formulated for parenteral delivery (e.g., intravenous delivery (IV)).B · US 10,940,156 B2 · ¶ 6
patent.fyi, US 2026/0355219 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355219/, SHA-256 f8f284fb0db87ca994821dde395548a21a680d8d03d6206812a9d72c1c165763